Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;16(11):855-8.
doi: 10.1016/j.cardfail.2010.06.414.

NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial

J Timothy Baldwin  1 , Douglas L Mann
Affiliations

NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial

J Timothy Baldwin et al. J Card Fail. 2010 Nov.

Abstract

Background: Ventricular assist devices (VADs) are used to bridge heart failure patients to transplantation, to allow their own hearts to recover, or as permanent ("destination") therapy. To date, the use of VADs has been limited to late-stage heart failure patients because of the associated device risks. In 2008, a National Heart, Lung, and Blood Institute (NHLBI) working group met to evaluate the treatment of heart failure using VADs and to advise the institute on how therapy for heart failure may be best advanced by clinical trials involving the devices.

Methods and results: Recognizing the improvements in VAD technology and in patient care and selection over the past decade, the working group recommended that a trial be performed to assess the use of chronic VAD therapy in patients who are less ill than those currently eligible for destination therapy. The hypothesis proposed for the trial is that VAD therapy may improve both survival and quality of life in moderately advanced heart failure patients who are neither inotrope-dependent nor exercise-intolerant and have not yet developed serious consequences such as malnourishment, end-organ damage, and immobility.

Conclusion: Based on the group's recommendations, NHLBI issued an RFP in 2009 for the REVIVE-IT Pilot Trail, which will serve to test the hypothesis and inform the pivotal trial.

PubMed Disclaimer

References

    1. Nabel EG. Shaping the Future of Research: The NHLBI Strategic Plan. Circ Res. 2007;101(9):849–50. - PubMed
    1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. N Engl J Med. 2001;345(20):1435–43. - PubMed
    1. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Second INTERMACS annual report: More than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29(1):1–10. - PMC - PubMed
    1. Lahpor JR. State of the art: implantable ventricular assist devices. Curr Opin Organ Transplant. 2009;14(5):554–9. - PubMed
    1. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device. N Engl J Med. 2009;361(23):2241–51. - PubMed